-
2022 The role of EBMT hematopoietic stem cell transplantation in mantle cell lymphoma: results of a single-center exploratory study
Time of Update: 2022-04-28
The early group planned to use autologous HSCT as consolidation therapy, but this regimen was not feasible due to poor patient condition or mobilization .
The study showed that in the late-stage group, autologous HSCT consolidation therapy combined with novel drugs was associated with improved survival .
-
What are the long-term benefits of Allo-HSCT in elderly patients with CR1 AML?
Time of Update: 2022-04-27
Table 2 Figure 1 Multivariate time-dependent Cox model showing that allo-HSCT was associated with a significantly lower risk of recurrence (73% risk reduction; HR [95% CI], 0.
allo-HSCT improves outcomes in ELN IR and UR AML patients aged >60 years in CR1 .
-
Anemia eat jujube?
Time of Update: 2022-04-27
However, studies have shown that while EPO treats anemia, it also causes tumor proliferation and metastasis, thereby aggravating tumor progression such as breast cancer and ovarian cancer, which greatly limits the treatment options for anemia in cancer patients .
-
The AAV gene therapy company founded by the Chinese uses a lower dose to treat hemophilia A doctor Mai Meng broke the news
Time of Update: 2022-04-27
Here are some examples of candidate products that are progressing faster: ➤ BioMarin's valoctocogene roxaparvovec (valrox) In January 2022, the company announced Complete data for valrox in Phase 3 clinical study GENEr8-1, 134 subjects met all primary and secondary efficacy endpoints in the two-year analysis.
-
A collection of research progress at the 2022 EBMT Annual Meeting
Time of Update: 2022-04-27
For details, please see: 2022 EBMT | ASCT still plays an important role in multiple myeloma patients in the era of new drugs Italian and Turkish researchers conducted studies to explore the use of allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia (AML) ( allo-HSCT) .
-
Leukemia: Oral thalidomide-cyclophosphamide-dexamethasone is an effective and safe regimen for relapsed/refractory adult Langerhans cell histiocytosis
Time of Update: 2022-04-24
A research team designed this prospective study to investigate the efficacy and safety of oral thalidomide combined with cyclophosphamide and dexamethasone (TCD) regimen in adult patients with relapsed/refractory LCH .
-
FDA Takes Caution Opinion on Rebrozyl for the Treatment of Nontransfusion Dependent (NTD) Beta Thalassemia
Time of Update: 2022-04-24
Bristol-Myers Squibb announced Friday that the FDA has extended its review of an application seeking expanded approval of Rebrozyl (luspatercept) for the treatment of adults with non-transfusion-dependent (NTD) beta thalassemia by three months .
-
"National Gene Sequencing Service Quality Status Survey" sincerely invites you to participate!
Time of Update: 2022-04-24
This survey aims to better understand the problems you encounter when using gene sequencing services, so as to provide you with better services .
This questionnaire is expected to take 3-5 minutes of your time .
-
Ann Hematol: Gut microbiota score predicts survival after allogeneic hematopoietic stem cell transplantation
Time of Update: 2022-04-24
C The 3-year cumulative transplant-related mortality (TRM) was significantly lower in the low group than in the high groupFigure 4: Cumulative gut microbiota (AIM) scores and their association with survival .
-
BJH: The impact of chronic lymphocytic leukemia on melanoma outcomes: a retrospective case-control study
Time of Update: 2022-04-24
Jobson, D McCormack, CJ Mar, V Tam, C Henderson, MA Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study Br J Haematol 2022 00 1 6https://doi.
-
J Clin Oncol: Long-term efficacy of B-cell maturation antigen and CD19 chimeric antigen receptor T-cell combination therapy in multiple myeloma
Time of Update: 2022-04-24
Combination of anti-B-cell maturation antigen and anti-CD19 chimeric antigen receptor T cells induces durable remission in patients with refractory or relapsed multiple myeloma, with a median progression-free survival of 18.
-
haematol: clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia
Time of Update: 2022-04-24
A foreign research team analyzed NF1, PTPN11, CBL, NRAS, and KRAS changes in 328 pediatric patients with AML to determine the clinical significance of these changes .
Molecular and cytogenetic abnormalities in 80 pediatric acute myeloid leukemia patients with altered RAS pathway .
-
Haematol: Methotrexate-Associated Central Neurotoxicity: Clinical Characteristics, Risk Factors, and Genome-Wide Association Studies in Children Treated with Acute Lymphoblastic Leukemia
Time of Update: 2022-04-24
Children receiving intrathecal (IT) methotrexate (MTX) were permanently missed after symptomatic MTX neurotoxicity (n=48) compared with children receiving IT MTX who continued to receive ALL in the central nervous system (CNS) There was an increased risk of recurrence (n=1,174) ( P =0.
-
Treatment of a case of autoimmune hemolytic anemia with strong cold agglutination
Time of Update: 2022-04-24
The method of using the RET channel for cold-aggregation sample processing:Viewing the RET-related parameters of the specimen, you can get the RBC-O result.
The RBC results of the impedance channel are more accurate, and then the corresponding red blood cell-related parameter results are obtained according to the calculation formula .
-
Am J Hematol; Long-term eltrombopag treatment leads to iron depletion in patients with bone marrow failure
Time of Update: 2022-04-24
A research team conducted a retrospective study of patients treated at the NIH for aplastic anemia, myelodysplastic syndrome, and monolineage cytopenias, comparing patients treated with EPAG to a historical cohort of immunosuppressive therapy without EPAG.
-
Nat Med: Axicabtagene ciloleucel as first-line treatment for high-risk large B-cell lymphoma
Time of Update: 2022-04-24
The primary outcome of the trial was complete response rate (CRR), and secondary outcomes were objective response rate (ORR), duration of response (DOR), event-free survival (EFS), progression-free survival (PFS), overall survival (OS), safety assessment, central nervous system (CNS) recurrence, CART cells and cytokine levels in blood .
-
Blood: Long-term efficacy of zanubrutinib in relapsed/refractory mantle cell lymphoma
Time of Update: 2022-04-24
The most common all-grade adverse reactions were decreased neutrophil count (46.
InfectIn conclusion, this study suggests that patients with relapsed/refractory mantle cell lymphoma can achieve durable remission with zanubrutinib with good safety .
-
Leuk Lymphoma: Association of elevated creatine kinase with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
Time of Update: 2022-04-24
Elevated creatine kinase (CK) is a common complication of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) and is associated with key treatment outcomes (overall survival (OS) and event-free survival (EFS) )) is still unknown .
-
Ann Hematol: Acute graft-versus-host disease increases the risk and accuracy of predictive models for transplant-associated thrombotic microangiopathy in patients with myelodysplastic syndromes
Time of Update: 2022-04-24
stem cell thrombosisThis study assessed risk factors for TA-TMA and developed a predictive model for this complication .
05) was used to establishFigure 3: Forest plot of odds ratios of different risk factors for TA-TMA in MDS patients after HSCT .
-
Professor Zhou Jianfeng, a well-known expert from Wuhan Tongji Hospital, died at the age of 57
Time of Update: 2022-04-24
The great god in my heart is Professor Zhou Jianfeng, Director of the Department of Hematology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan .
The great god in my heart is Professor Zhou Jianfeng, Director of the Department of Hematology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan .
